IPSEN – Buy-back programme – Art 5 of MAR – Week 32 – 2024
- 13 August 2024 - 1 mins read
Aggregated presentation by day and by market
| Purchases of own shares from August 5th to August 7th, 2024 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/08/2024 | FR0010259150 | 9 021 | 103,0295 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/08/2024 | FR0010259150 | 4 119 | 102,9704 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/08/2024 | FR0010259150 | 727 | 102,9999 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/08/2024 | FR0010259150 | 989 | 103,0782 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/08/2024 | FR0010259150 | 7 492 | 102,8158 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/08/2024 | FR0010259150 | 2 387 | 102,8565 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/08/2024 | FR0010259150 | 455 | 102,7316 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/08/2024 | FR0010259150 | 634 | 102,6875 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 07/08/2024 | FR0010259150 | 2 153 | 103,0974 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 07/08/2024 | FR0010259150 | 1 000 | 103,1034 | CEUX |
| TOTAL | 28 977 | 102,9480 | ||||
Attachment
09 December 2024
1 mins read
Ipsen – November 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
07 November 2024
1 mins read
Ipsen – October 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
09 October 2024
1 mins read
Ipsen – September 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
18 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
15 September 2024
7 mins read
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
04 September 2024
1 mins read
Ipsen – August 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
30 August 2024
1 mins read
Testing video 1
30 August 2024
1 mins read
Testing video 3
30 August 2024
1 mins read